Donald Trump is using the threat of steep tariffs to pressure pharmaceutical companies into lowering drug prices in the US market.
Under the proposal, companies that refuse to strike price-reduction deals would face 100% tariffs on their products. The tariff structure specifically targets branded medications and their active pharmaceutical ingredients, while leaving the broader generic drug market untouched for at least a year.
Generic drugs, which account for more than 90% of all medications dispensed in the US, would remain exempt from the tariff penalties during that initial period. Other categories including orphan drugs, veterinary pharmaceuticals, and specialty medicines would also avoid tariffs if they come from countries with existing trade agreements or address urgent public health needs.
The strategy combines punitive trade measures with negotiation leverage, potentially reshaping how drugmakers approach pricing discussions with the federal government. By protecting generics from immediate tariff consequences, the approach avoids disrupting the segment of the pharmaceutical market most relied upon for affordable treatment options.
Comments